Navigation Links
Inflamax Research Inc. Announces the Successful Completion of Enrollment for the First Multi-center, Mobile Environmental Exposure Chamber (mEEC™) Study
Date:3/4/2016

This is a landmark clinical study and is the first allergy immunotherapy study to utilize the mEEC™ in the United States. Inflamax’s unique and world leading technology was used to recruit and study patients in two separate locations in Neptune, New Jersey and Cincinnati, Ohio. The unique challenge in enrolling before the start of the tree season in the Northeast US was met with the deployment of Inflamax’s unique Online Central Recruiting Update Platform (OCRUP™). The data from this study will be instrumental in the launch of the Phase III program prior to end of 2016 utilizing Inflamax’s mEEC™ system in several locations within the United States. We also wish to thank the 20 investigator sites in Ohio, Kentucky, New Jersey, New York and Pennsylvania.

“Allergy trials rely on mother nature to produce consistent pollen concentrations to elicit adequate levels of symptoms in order to prove dose-response or efficacy. Unfortunately, climate change and variability in patient exposure in their everyday lives can lead to large variabilities and recruitment delays should the environment, weather, and other factors, not produce consistently. The novel mEEC™ technology enables study designs and endpoints to be infinitely more robust and allows for studying allergen-specific therapies, such as immunotherapy. The mEEC™ model is designed to provide consistent allergen exposure, over time, significantly reducing data variability and compliance compared to traditional field studies”, commented Dr. Anne Marie Salapatek, Chief Scientific Officer at Inflamax Research Inc.

Allergy Therapeutics® is a specialty pharmaceutical company focused upon the development of treatments for allergy. Allergy Therapeutics has an existing sales base of approximately £40 million per annum, an MHRA-approved manufacturing capability, as well as an established sales and marketing infrastructure in several major European markets. In addition, the Company has a number of novel compounds which have already undergone initial clinical evaluation and, once registered, could potentially revolutionize the treatment of allergy.

Inflamax Research is a global full-service, CRO specializing in allergy, respiratory, ocular and dermatology Phase I-IV research, led by world-known, key-opinion leaders. Inflamax has a strong scientific capability and publishes extensively in peer-reviewed journals. Inflamax’s Clinical Trial Management group has experience in conducting large multi-center trials in these, and other, therapeutic areas. Inflamax offers full-service including study design/concept development, medical writing, site management, monitoring, data management, statistics, and CSR development.

Read the full story at http://www.prweb.com/releases/2016/03/prweb13247151.htm.


'/>"/>
Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved


Related biology technology :

1. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
2. Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation.
3. Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc.
4. Inflamax Research, Inc. Announces Fully-Integrated Clinical e-Source Data Management Services
5. Inflamax Research CSO to Present Data Demonstrating the Utility of Environmental Exposure Chambers in Asthma & Allergic Rhinitis Research at ERS 2014
6. Inflamax’s Dir. of Data Management to attend Society for Clinical Data Management Conference in Las Vegas as SME for electronic data capture section of GCDMP guide
7. Inflamax Research Unveils a Transformative New Brand and Logo
8. Inflamax Research Announces Positive Results of a Phase IIa Allergic Conjunctivitis Trial Testing a Novel Aldehyde-Trapping Molecule from Aldeyra Therapeutics
9. Peptide Therapeutics Market is Expected to Reach USD 25.4 Billion Globally in 2018: Transparency Market Research
10. Lupus Research Institute Requests Strengthened NIH Funding for Biomedical Research in Debilitating Diseases like Lupus
11. Guidepoint Global Launches Two Major Enhancements to its Client Research Portal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2017)... , ... May 19, 2017 , ... ... Proof-of-Concept Program. Academic researchers with technologies ripe for commercialization, and who are ... and Delaware, are encouraged to submit proposals. QED, now in its tenth round, ...
(Date:5/18/2017)... ... May 16, 2017 , ... Clinical Supplies Management (“CSM”), a Great Point ... continues to grow. CSM has doubled in size over the past six months ... growth strategy. , Roger Gasper joins CSM as Chief Financial Officer. Roger has ...
(Date:5/18/2017)... ... May 17, 2017 , ... Cognition ... and commercialization, has just released version 9.0 of the Cognition Cockpit platform. , ... of Cockpit,” says David Cronin, CEO of Cognition. “We’re thrilled to finally be ...
(Date:5/18/2017)... ... May 17, 2017 , ... G-CON Manufacturing, ... Chief Executive Officer, Maik Jornitz, was recognized as a Top 10 Industry Influencer ... 100 individuals “involved in bettering the pharma industry and bringing life-changing medicines to ...
Breaking Biology Technology:
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
Breaking Biology News(10 mins):